Insider Trading February 27, 2026

Becton Dickinson EVP Executes Small Stock Sale Amid Strong Q1 Results and Debt Tender Plans

Chief Revenue Officer disposes of 75 shares under a 10b5-1 plan as the company posts modest revenue growth and unveils large debt buyback offers

By Derek Hwang BDX
Becton Dickinson EVP Executes Small Stock Sale Amid Strong Q1 Results and Debt Tender Plans
BDX

Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co, sold 75 shares of company stock on February 26, 2026, under a pre-arranged Rule 10b5-1 plan. The transaction, worth $13,638, leaves Feld with 21,308 shares after adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. The sale comes as Becton Dickinson reported fiscal first-quarter 2026 results that beat revenue and earnings expectations and announced tender offers to repurchase up to $1.6 billion of outstanding debt across 15 series. Several analysts adjusted price targets following the results.

Key Points

  • Michael Feld sold 75 shares of Becton Dickinson stock at $181.84 on February 26, 2026, for $13,638 and now directly holds 21,308 shares after adjustments related to the combination with Waters Corp.
  • The transaction was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025, indicating a pre-arranged sale schedule.
  • Becton Dickinson reported fiscal Q1 2026 revenue of $5.25 billion, up 0.4% year-over-year and above Wall Street estimates, with EPS of $2.91, and announced tender offers to buy up to $1.6 billion of outstanding debt across 15 series; several brokerages adjusted price targets following the results.

Michael Feld, who serves as Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE: BDX), completed a sale of 75 shares of the company on February 26, 2026. The shares changed hands at $181.84 each, producing a total transaction value of $13,638.

Following this disposition, Feld is recorded as directly owning 21,308 shares of Becton Dickinson common stock. That holdings figure accounts for adjustments tied to the integration of the company’s Biosciences and Diagnostic Solutions units with Waters Corp.

The sale was carried out under a pre-established Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. The use of such a plan indicates the transaction was part of a previously arranged schedule for trading company shares.

These insider trading details arrive alongside Becton Dickinson’s fiscal first-quarter 2026 financial report, which showed revenue of $5.25 billion, a 0.4% increase compared with the prior year. The revenue figure exceeded Wall Street projections of $5.15 billion and outperformed the company’s internal guidance, which had anticipated a low-single-digit decline.

Earnings per share for the quarter were $2.91, surpassing consensus forecasts by $0.10. In conjunction with those results, Becton Dickinson announced plans to launch tender offers to repurchase up to $1.6 billion of its outstanding debt securities, spanning 15 separate series.

Market analysts responded to the quarterly disclosure and the company’s strategic moves by adjusting price targets. RBC Capital lowered its target to $172 while retaining a Sector Perform rating. Piper Sandler cut its target to $170 and kept a Neutral rating. Jefferies established a new target of $190 while maintaining a Buy rating. These revisions reflect a mix of sentiment about near-term growth prospects and the financial actions the company is taking.


Financial and market context contained in this report is limited to the figures and statements supplied by the company and analysts noted above. No additional forecasts or external commentary are included.

Risks

  • The company’s modest revenue growth and analyst adjustments to price targets indicate ongoing uncertainty about near-term growth, which could affect investor sentiment in the healthcare and medical devices sectors.
  • The tender offers to repurchase up to $1.6 billion in debt represent a significant financial maneuver that may carry execution and market risks for corporate credit and the company’s capital structure.
  • Changes in analyst price targets reflect differing views on valuation and outlook, introducing uncertainty for equity market participants and institutional investors focused on medical device stocks.

More from Insider Trading

Howmet Aerospace Vice President Disposes of $260,005 in Stock Ahead of Major Acquisition Close Feb 27, 2026 Bristow COO Stavley Sells Stake as Shares Trade Near 52-Week Peak Feb 27, 2026 Innovex Co-Investors Sell $162.6 Million Stake in Single-Day Block Trade Feb 27, 2026 Patrick Industries Director Adds to Stake as Shares Slip; Analysts Lift Targets After Strong Q4 Feb 27, 2026 Trupanion CFO Disposes of $118,958 in Stock; RSUs Converted on Same Day Feb 27, 2026